CNS Lymphoma Epidemiology Forecast 2025-2034

Primary central nervous system lymphoma (PCNSL) is an extranodal non-Hodgkin lymphoma that affects the brain, spine, cerebrospinal fluid (CSF), or vitreoretinal space. It is a rare cancer that affects 0.4 out of every 100,000 people annually in all age groups, but in people over 70, the incidence rises to 4 out of every 100,000.

CNS Lymphoma Epidemiology Forecast Report Coverage

The “CNS Lymphoma Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of CNS lymphoma. It projects the future incidence and prevalence rates of CNS Lymphoma across various populations. The study covers age and type as major determinants of the CNS lymphoma-affected population. The report highlights patterns in the prevalence of CNS lymphoma over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of CNS lymphoma in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

CNS Lymphoma: Disease Overview

Primary central nervous system lymphoma (PCNSL) is a rare, aggressive non-Hodgkin lymphoma that starts in the brain, spinal cord, leptomeninges, or eyes and does not spread throughout the body. It mainly affects immunocompromised people, such as those with HIV/AIDS or those recovering from transplants, although immunocompetent people can also get it. Symptoms include the worsening of neurological effects, such as changes in vision, focal deficits, and cognitive decline. MRI, cerebrospinal fluid (CSF) analysis, and brain biopsy are commonly used in diagnosis to verify the existence of malignant lymphocytes.

CNS Lymphoma: Treatment Overview

Primary central nervous system lymphoma (PCNSL) is usually treated with high-dose chemotherapy based on methotrexate, frequently in combination with rituximab or cytarabine. Because of the potential for neurotoxicity, whole-brain radiation therapy (WBRT) is typically avoided in younger patients, though it may be used in refractory cases. For qualified patients with recurrent or refractory disease, autologous stem cell transplantation is taken into consideration. Although corticosteroids can temporarily reduce symptoms, using them prior to a biopsy may make diagnosis more difficult.

Epidemiology

The CNS Lymphoma epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for CNS lymphomas by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for CNS lymphoma and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• Central nervous system lymphoma also known as primary central nervous system lymphoma accounts 4% to 6% of all extranodal lymphomas and 4% of newly discovered malignant brain tumors.
• PCNSL diagnosis necessitates a high degree of suspicion as the clinical presentations vary. Just about half to 70% of PCNSL patients will exhibit focal neurologic deficits. Over the course of a few weeks to months, patients with PCNSL (approximately 40% to 50%) may experience nonspecific behavioral or cognitive changes. Although they are not always easily recognized as neurologic, symptoms of increased intracranial pressure, such as headache, nausea, or vomiting, can also be observed (33%).
• Diffuse large B-Cell lymphoma (DLBCLs) account for 90% of PCNSL tumors, and the activated B-cell-like (ABC)/nongerminal center subtype accounts for the great majority of these.
• With an annual incidence rate of 0.5 per 100,000 in the United States, PCNSL is a rare disease that accounts for only 4-6% of all extranodal lymphomas and roughly 4% of newly diagnosed CNS tumors. 2. As the population ages, PCNSL incidence is continuously rising.

Country-wise CNS Lymphoma Epidemiology

The CNS lymphoma epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of CNS lymphoma varies significantly between countries due to differences in factors such as genetic mutations, increasing geriatric population, environmental factors, among others. Finland has one of the highest reported incidences of PCNSL worldwide. The incidence increased by 2.4% annually. The outlook remains bleak, particularly for older patients.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of CNS lymphoma based on several factors.
• CNS Lymphoma Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of CNS lymphoma are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of CNS lymphoma epidemiology in the 8 major markets?
• What will be the total number of patients with CNS lymphoma across the 8 major markets during the forecast period?
• What was the country-wise prevalence of CNS lymphoma in the 8 major markets in the historical period?
• Which country will have the highest number of CNS lymphoma patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of CNS lymphoma during the forecast period of 2025-2034?
• What are the currently available treatments for CNS lymphoma?
• What are the disease risks, signs, symptoms, and unmet needs of CNS lymphoma?

This product will be delivered within 3-5 business days.